OMGA - Novo Nordisk Flagship to develop next-generation obesity drugs
2024-05-09 13:22:28 ET
More on Novo Nordisk
- The FTC Cracks Down On Novo Nordisk's Ozempic
- Novo Nordisk A/S 2024 Q1 - Results - Earnings Call Presentation
- Novo Nordisk A/S (NVO) Q1 2024 Earnings Call Transcript
- Catalent, Novo Nordisk receive FTC request for more information
- GLP-1 drug prices falling at UK pharmacies, clinics: report